Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2/STAT3 signaling pathway

• Published in: International journal of biological sciences 2024, Vol.20 (11), p.4314-4340
• Main Authors: Yang, Boshen, Li, Taixi, Wang, Zhixiang, Zhu, Yuankang, Niu, Kaifan, Hu, Sien, Lin, Zhiqi, Zheng, Xinjie, Jin, Xian, Shen, Chengxing
• Format: Article
• Language: English
• Subjects: Animals; Cardiomyopathies - drug therapy; Cardiomyopathies - metabolism; Cellular Senescence - drug effects; Disease Models, Animal; Janus Kinase 2 - metabolism; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Nitriles - pharmacology; Nitriles - therapeutic use; Pyrazoles - pharmacology; Pyrazoles - therapeutic use; Pyrimidines - pharmacology; Pyrimidines - therapeutic use; Rats; Rats, Sprague-Dawley; Sepsis - drug therapy; Sepsis - metabolism; Signal Transduction - drug effects; STAT3 Transcription Factor - metabolism
• ISSN: 1449-2288; 1449-2288
• DOI: 10.7150/ijbs.96489

Cellular senescence has emerged as a pivotal focus in cardiovascular research. This study investigates the previously unrecognized role of cellular senescence in septic cardiomyopathy (SCM) and evaluates senomorphic therapy using ruxolitinib (Rux) as a potential treatment option. We employed lipopolysaccharide (LPS)-induced neonatal rat cardiomyocytes (NRCMs) and two mouse models-LPS-induced and cecal ligation and puncture (CLP)-induced SCM models-to assess Rux's effects. RNA sequencing, western blotting (WB), quantitative polymerase chain reaction (qPCR), immunofluorescence, immunohistochemistry, senescence-associated β-galactosidase (SA-β-gal) assay, and other techniques were utilized to investigate underlying mechanisms. Senescence-associated secretory phenotype (SASP) and cellular senescence markers were markedly elevated in LPS-induced NRCMs and SCM animal models, confirmed by the SA-β-gal assay. Rux treatment attenuated SASP and , alongside downregulation of senescence markers. Moreover, Rux-based senomorphic therapy mitigated mitochondrial-mediated apoptosis, improved cardiac function in SCM mice, restored the balance of antioxidant system, and reduced reactive oxygen species (ROS) levels. Rux treatment restored mitochondrial membrane potential, mitigated mitochondrial morphological damage, and upregulated mitochondrial complex-related gene expression, thereby enhancing mitochondrial function. Additionally, Rux treatment ameliorated SCM-induced mitochondrial dynamic dysfunction and endoplasmic reticulum stress. Mechanistically, Rux inhibited JAK2-STAT3 signaling activation both and . Notably, low-dose Rux and ABT263 showed comparable efficacy in mitigating SCM. This study highlighted the potential significance of cellular senescence in SCM pathogenesis and suggested Rux-based senomorphic therapy as a promising therapeutic approach for SCM.